A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cell transplantation
Phase of Trial: Phase III
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Ruxolitinib (Primary) ; Everolimus; Imatinib; Infliximab; Methotrexate; Mycophenolate mofetil; Pentostatin; Sirolimus
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms REACH3
- Sponsors Incyte Corporation; Novartis; Novartis Pharma A.G.
- 21 Jun 2018 According to an Incyte Corporation media release, data from this trial are expected in 2019.
- 23 Jun 2017 Status changed from not yet recruiting to recruiting.
- 07 Apr 2017 Status changed from planning to not yet recruiting.